Two studies came out earlier this week in JAMA Internal Medicine stating that there is a potential link between cannabis legalization and a decrease in the amount of prescriptions for opioids (1,2).
The annual Pittcon Conference and Expo was held February 26–March 1, 2018, in Orlando, Florida, and featured a few tracks and special events dedicated to cannabis science.
The 4th annual Emerald Conference hosted by Emerald Scientific was held February 15–16, 2018, in San Diego, California.
The agencies sent warning letters to several companies that the agencies say are illegally marketing unapproved products to treat opioid addiction and withdrawal.
As I look around today, there is certainly no shortage of cannabis-related conferences and trade shows.
Medical use of marijuana for a broad range of conditions is expanding rapidly in the US, as legalization gathers pace and investors flock to a booming market.
On Nov. 1, 2017, FDA announced that it issued warning letters to four companies illegally selling products online that claim to prevent, diagnose, treat, or cure cancer without evidence to support these statements.
Efficient synthesis of complex cannabinoids is possible while avoiding marijuana cultivation.
On Feb. 7, 2017 GW Pharmaceuticals announced the results from a small Phase II study with tetrahydrocannabinol (THC) and cannabidiol (CBD) in 21 patients with recurrent glioblastoma multiforme (GBM).
AXIM Biotechnologies, a Netherlands-based biotechnology company, announced that it would be entering clinical trials with its patent-pending cannabigerol (CBG) topical ointment formulation AX-1602, the company said in a May 16, 2016 press